KROS stock forecast, quote, news & analysis
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more
Keros Therapeutics (KROS) Stock Analysis: Pipeline Promise Versus the Cash Burn Clock
Key Takeaways
- Keros Therapeutics shares traded near $10.21 as of late July 2026, hovering just above the 52-week low of $9.69 and down roughly 7% over the trailing 30-day period.
- The company's lead clinical candidates — rinvatercept for Duchenne muscular dystrophy and ALS, and elritercept for myelodysplastic syndromes and myelofibrosis — continue advancing through development, representing the core value proposition for investors.
- First-quarter 2026 results disappointed, with an EPS loss of $1.21 versus consensus estimates of a $1.02 loss and revenue of $0.37 million significantly below the expected $1.93 million, intensifying focus on the company's cash runway.
- Wall Street consensus rates KROS a Hold, with an average 12-month price target of approximately $20.40, implying substantial upside relative to current levels but tempered by near-term execution risks.
- Second-quarter 2026 earnings, anticipated in early August, stand out as the next pivotal event likely to shape sentiment around the stock.
Current Market Snapshot
Keros Therapeutics shares have settled into a low-volatility range in recent weeks after a steeper decline earlier in 2026. The stock is trading well below both its 50-day moving average of approximately $10.92 and its 200-day moving average near $13.42, indicating persistent technical weakness. With a market capitalization around $218 million and a 52-week range spanning $9.69 to $22.55, KROS sits near the bottom of its annual trading band. Institutional investors hold roughly 71.6% of outstanding shares, reflecting continued professional interest despite the challenging price action. The broader biotech sector has faced headwinds from higher-for-longer interest rate expectations, which tend to pressure pre-revenue clinical-stage companies that rely on capital markets for funding.
Keros Therapeutics (KROS) Business Overview and Competitive Position
Keros Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of protein therapeutics that target dysfunctional signaling in the transforming growth factor-beta (TGF-β) family of proteins. TGF-β pathways serve as master regulators of growth, repair, and maintenance across multiple tissue types — including skeletal muscle, bone, adipose tissue, heart, and blood. Keros has built a differentiated scientific platform by decoding how these signaling pathways can be therapeutically modulated. Its lead product candidate, rinvatercept, is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). Its most clinically advanced candidate, elritercept, targets cytopenias — including anemia and thrombocytopenia — in patients with myelodysplastic syndrome (MDS) and myelofibrosis. Both programs address diseases with significant unmet medical need and limited treatment options, positioning Keros in high-value rare-disease and hematology markets.
Recent Developments Driving KROS
Several events have shaped investor sentiment over the past month. On June 25, 2026, Keros announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors effective July 1. Dr. Prener brings deep clinical development and executive leadership experience from senior roles at Imbria Pharmaceuticals, Freeline Therapeutics, Novo Nordisk, and Baxalta, as well as current advisory and board positions. Her addition is widely viewed as a strategic move to strengthen governance as the pipeline matures toward later-stage trials.
Earlier in June, President and CEO Jasbir S. Seehra, Ph.D., presented at the Goldman Sachs 47th Annual Global Healthcare Conference, providing visibility into the company's R&D roadmap. At the June 3 annual shareholder meeting, stockholders approved all governance proposals and elected Jean-Jacques Bienaimé and Charles Newton to the board. On the insider activity front, Chair Bienaimé purchased 1,000 shares in mid-July, while other directors executed planned sales under pre-arranged Rule 10b5-1 trading plans — a mixed signal that has not moved the needle decisively in either direction.
The May 14 Q1 2026 earnings miss continues to weigh on sentiment. The wider-than-expected loss and revenue shortfall raised questions about the pace of collaboration and licensing income, as well as the burn rate on R&D spending. Analysts at Wall Street Zen and Weiss Ratings downgraded the stock following the report, contributing to the downward pressure.
Trending AI Robots
For traders seeking data-driven signals in stocks like KROS, Tickeron's Trending AI Robots page offers a curated view into AI-powered trading strategies. Tickeron hosts hundreds of AI trading bots that collectively monitor thousands of tickers across equity markets, but only a select group of top-performing and contextually relevant bots appears in this dynamically updated section. These bots span diverse strategies, timeframes, and performance metrics — from short-term momentum algorithms to longer-duration trend-following models — providing traders with real-time signals grounded in technical and fundamental analysis. Exploring the Trending AI Robots page can help investors identify actionable patterns and stay ahead of shifts in market sentiment without manually sifting through endless data.
2026 Outlook and What Investors Should Watch
The most immediate catalyst for KROS is the company's second-quarter 2026 earnings report, expected around August 5. Investors will scrutinize both the bottom-line figures and any updates on clinical trial enrollment, data readout timelines, and partnership or licensing revenue. Cash runway remains a central concern — with a net loss trajectory and limited revenue from collaborations, the company's ability to fund operations without dilutive capital raises will be closely monitored.
Beyond quarterly numbers, clinical milestones for elritercept and rinvatercept are the long-term value drivers. Any interim data releases, regulatory designations, or partnership announcements could materially shift the risk-reward profile. On the macro side, Federal Reserve policy and biotech sector fund flows will continue to influence appetite for pre-revenue names like Keros. Analysts currently project full-year 2026 EPS around negative $5.19, with expectations for further losses in 2027, underscoring that KROS remains a story stock tied to binary clinical outcomes rather than near-term profitability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KROS in upward trend: price rose above 50-day moving average on August 06, 2026
KROS moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend. In of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on KROS as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for KROS just turned positive on August 06, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on July 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
KROS broke above its upper Bollinger Band on August 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KROS entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.847) is normal, around the industry mean (20.121). P/E Ratio (4.778) is within average values for comparable stocks, (25.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.855). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (466.660).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KROS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology